S
SpyGlass Pharma
Developing novel technologies to improve the quality of life
About SpyGlass Pharma
SpyGlass Pharma is a privately-held biotechnology company that operates in the ophthalmic industry. The company has developed a unique intraocular drug delivery platform designed to aid cataract surgeons in managing glaucoma patients. This platform is the world's first intraocular lens (IOL) mounted, controlled release drug delivery system capable of delivering multiple years of therapy.
The device is designed to be implanted during routine cataract surgery and releases a consistent daily dose of the drug bimatoprost, a medication used to treat glaucoma. The drug is released over a targeted period of three years, providing a long-term solution for patients. This method of drug delivery is independent of patient behavior, addressing the industry-wide issue of patient non-adherence to glaucoma medication, which can lead to disease progression and vision loss.
SpyGlass Pharma's business model revolves around providing this innovative solution to the millions of glaucoma patients who undergo cataract surgery each year. The company generates revenue by selling its drug delivery platform to healthcare providers.
Currently, the SpyGlass Pharma Drug Delivery Platform is undergoing a Phase I/II clinical trial. It's important to note that the platform has not yet been approved by the FDA.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Feb 2026 | $150M | $842M | Undisclosed | ↗ |
| SERIES DOther financing | Jun 2025 | $75M | $450M | NEA · Vensana Capital · Gilde Healthcare · RA Capital Management | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for SpyGlass Pharma is 5.7K monthly website visits, up 35.7% over the last three months. SpyGlass Pharma's team grew 23.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
SpyGlass Pharma in the Aliso Viejo ecosystem
The SpyGlass Pharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
NEA
Vensana Capital
Series B and later5 investors entered at this stage
RA Capital Management
Samsara BioCapital
Vertex Ventures HC
Sands Capital Management
Gilde Healthcare
Other known investors1 additional known investor
University of Colorado
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SpyGlass Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SpyGlass Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









